Breaking News, Collaborations & Alliances

Rigel, Grifols Enter License Agreement

To commercialize fostamatinib disodium hexahydrate in all potential indications in Europe and Turkey

Rigel Pharmaceuticals, Inc. has entered into an exclusive license and supply agreement with Grifols, S.A  to commercialize fostamatinib disodium hexahydrate in all potential indications in Europe and Turkey.  Grifols is a global healthcare company and a leading producer of plasma-derived medicines for the treatment of rare and chronic diseases, including intravenous immunoglobulin (IVIG) which is used in the treatment of ITP and AIHA. Fostamatinib is commercially available in the U.S. under t...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters